Speedking Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 31-12-2024
- Paid Up Capital ₹ 0.50 M
as on 31-12-2024
- Company Age 19 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
About Speedking Pharma
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Nirav Shah, Karl Surty, Jayesh Pancholi, and One other member serve as directors at the Company.
- CIN/LLPIN
U51397MH2005PTC152219
- Company No.
152219
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Mar 2005
- Date of AGM
23 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Speedking Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nirav Shah  | Whole-Time Director | 28-Mar-2005 | Current |
| Karl Surty | Director | 19-Jul-2021 | Current |
| Jayesh Pancholi | Director | 10-Feb-2020 | Current |
| Devina Shah | Director | 01-Jan-2018 | Current |
Financial Performance of Speedking Pharma.
Speedking Pharma Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Speedking Pharma?
In 2017, Speedking Pharma had a promoter holding of 99.94% and a public holding of 0.06%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Luckystar Pharma Private LimitedActive 7 years 8 months
Nirav Shah, Karl Surty and 2 more are mutual person
- Celebrate Services Private LimitedActive 29 years 6 months
Nirav Shah and Devina Shah are mutual person
- Sevenstar Realtek Private LimitedActive 67 years 8 months
Nirav Shah and Devina Shah are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Speedking Pharma?
Speedking Pharma has a workforce of 76 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Speedking Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Speedking Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
